These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1124 related items for PubMed ID: 18281615

  • 21. Multiple kinase pathways involved in the different de novo sensitivity of pancreatic cancer cell lines to 17-AAG.
    Liu H, Zhang T, Chen R, McConkey DJ, Ward JF, Curley SA.
    J Surg Res; 2012 Jul; 176(1):147-53. PubMed ID: 22099584
    [Abstract] [Full Text] [Related]

  • 22. The HSP90 inhibitor 17-N-allylamino-17-demethoxy geldanamycin (17-AAG) synergizes with cisplatin and induces apoptosis in cisplatin-resistant esophageal squamous cell carcinoma cell lines via the Akt/XIAP pathway.
    Ui T, Morishima K, Saito S, Sakuma Y, Fujii H, Hosoya Y, Ishikawa S, Aburatani H, Fukayama M, Niki T, Yasuda Y.
    Oncol Rep; 2014 Feb; 31(2):619-24. PubMed ID: 24317439
    [Abstract] [Full Text] [Related]

  • 23. Involvement of PI3K/Akt signaling pathway in hepatocyte growth factor-induced migration of uveal melanoma cells.
    Ye M, Hu D, Tu L, Zhou X, Lu F, Wen B, Wu W, Lin Y, Zhou Z, Qu J.
    Invest Ophthalmol Vis Sci; 2008 Feb; 49(2):497-504. PubMed ID: 18234991
    [Abstract] [Full Text] [Related]

  • 24. Formation of 17-allylamino-demethoxygeldanamycin (17-AAG) hydroquinone by NAD(P)H:quinone oxidoreductase 1: role of 17-AAG hydroquinone in heat shock protein 90 inhibition.
    Guo W, Reigan P, Siegel D, Zirrolli J, Gustafson D, Ross D.
    Cancer Res; 2005 Nov 01; 65(21):10006-15. PubMed ID: 16267026
    [Abstract] [Full Text] [Related]

  • 25. Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol.
    Solit DB, Basso AD, Olshen AB, Scher HI, Rosen N.
    Cancer Res; 2003 May 01; 63(9):2139-44. PubMed ID: 12727831
    [Abstract] [Full Text] [Related]

  • 26. Expression of focal adhesion kinase in uveal melanoma and the effects of Hsp90 inhibition by 17-AAG.
    Faingold D, Filho VB, Fernandes B, Jagan L, de Barros AM, Orellana ME, Antecka E, Burnier MN.
    Pathol Res Pract; 2014 Nov 01; 210(11):739-45. PubMed ID: 25041838
    [Abstract] [Full Text] [Related]

  • 27. 17-AAG inhibits vemurafenib-associated MAP kinase activation and is synergistic with cellular immunotherapy in a murine melanoma model.
    Joshi SS, Jiang S, Unni E, Goding SR, Fan T, Antony PA, Hornyak TJ.
    PLoS One; 2018 Nov 01; 13(2):e0191264. PubMed ID: 29481571
    [Abstract] [Full Text] [Related]

  • 28. Comparison of 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: effects on Hsp90 and client proteins in melanoma models.
    Smith V, Sausville EA, Camalier RF, Fiebig HH, Burger AM.
    Cancer Chemother Pharmacol; 2005 Aug 01; 56(2):126-37. PubMed ID: 15841378
    [Abstract] [Full Text] [Related]

  • 29. Cooperative inhibitory effect of ZD1839 (Iressa) in combination with 17-AAG on glioma cell growth.
    Premkumar DR, Arnold B, Pollack IF.
    Mol Carcinog; 2006 May 01; 45(5):288-301. PubMed ID: 16550610
    [Abstract] [Full Text] [Related]

  • 30. Human melanoma cells expressing V600E B-RAF are susceptible to IGF1R targeting by small interfering RNAs.
    Yeh AH, Bohula EA, Macaulay VM.
    Oncogene; 2006 Oct 26; 25(50):6574-81. PubMed ID: 16715137
    [Abstract] [Full Text] [Related]

  • 31. The heat shock protein 90 inhibitor 17-AAG induces cell cycle arrest and apoptosis in mantle cell lymphoma cell lines by depleting cyclin D1, Akt, Bid and activating caspase 9.
    Georgakis GV, Li Y, Younes A.
    Br J Haematol; 2006 Oct 26; 135(1):68-71. PubMed ID: 16925576
    [Abstract] [Full Text] [Related]

  • 32. HSP90 inhibition induces cytotoxicity via down-regulation of Rad51 expression and DNA repair capacity in non-small cell lung cancer cells.
    Ko JC, Chen HJ, Huang YC, Tseng SC, Weng SH, Wo TY, Huang YJ, Chiu HC, Tsai MS, Chiou RY, Lin YW.
    Regul Toxicol Pharmacol; 2012 Dec 26; 64(3):415-24. PubMed ID: 23069143
    [Abstract] [Full Text] [Related]

  • 33. Potent activity of a novel dimeric heat shock protein 90 inhibitor against head and neck squamous cell carcinoma in vitro and in vivo.
    Yin X, Zhang H, Burrows F, Zhang L, Shores CG.
    Clin Cancer Res; 2005 May 15; 11(10):3889-96. PubMed ID: 15897590
    [Abstract] [Full Text] [Related]

  • 34. [The heat shock protein 90 inhibitor induces apoptosis and differentiation of Kasumi-1 and its mechanisms].
    Yu WJ, Rao Q, Wang M, Tian Z, Liu XR, Lin D, Wang JX.
    Zhonghua Xue Ye Xue Za Zhi; 2005 Dec 15; 26(12):728-31. PubMed ID: 16620576
    [Abstract] [Full Text] [Related]

  • 35. Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myeloma.
    Francis LK, Alsayed Y, Leleu X, Jia X, Singha UK, Anderson J, Timm M, Ngo H, Lu G, Huston A, Ehrlich LA, Dimmock E, Lentzsch S, Hideshima T, Roodman GD, Anderson KC, Ghobrial IM.
    Clin Cancer Res; 2006 Nov 15; 12(22):6826-35. PubMed ID: 17121904
    [Abstract] [Full Text] [Related]

  • 36. FLT3 expressing leukemias are selectively sensitive to inhibitors of the molecular chaperone heat shock protein 90 through destabilization of signal transduction-associated kinases.
    Yao Q, Nishiuchi R, Li Q, Kumar AR, Hudson WA, Kersey JH.
    Clin Cancer Res; 2003 Oct 01; 9(12):4483-93. PubMed ID: 14555522
    [Abstract] [Full Text] [Related]

  • 37. Pyrophosphorolysis detects B-RAF mutations in primary uveal melanoma.
    Maat W, Kilic E, Luyten GP, de Klein A, Jager MJ, Gruis NA, Van der Velden PA.
    Invest Ophthalmol Vis Sci; 2008 Jan 01; 49(1):23-7. PubMed ID: 18172070
    [Abstract] [Full Text] [Related]

  • 38. Involvement of mitochondrial and B-RAF/ERK signaling pathways in berberine-induced apoptosis in human melanoma cells.
    Burgeiro A, Gajate C, Dakir el H, Villa-Pulgarín JA, Oliveira PJ, Mollinedo F.
    Anticancer Drugs; 2011 Jul 01; 22(6):507-18. PubMed ID: 21527846
    [Abstract] [Full Text] [Related]

  • 39. Human leukemias with mutated FLT3 kinase are synergistically sensitive to FLT3 and Hsp90 inhibitors: the key role of the STAT5 signal transduction pathway.
    Yao Q, Nishiuchi R, Kitamura T, Kersey JH.
    Leukemia; 2005 Sep 01; 19(9):1605-12. PubMed ID: 16034464
    [Abstract] [Full Text] [Related]

  • 40. Activation of the FGF2/FGFR1 autocrine loop for cell proliferation and survival in uveal melanoma cells.
    Lefèvre G, Babchia N, Calipel A, Mouriaux F, Faussat AM, Mrzyk S, Mascarelli F.
    Invest Ophthalmol Vis Sci; 2009 Mar 01; 50(3):1047-57. PubMed ID: 19029025
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 57.